Introduction
In the healthcare field, these topics are particularly valuable for research, as the outcomes of healthcare services depend on them. Those in the medical domain must understand pharmacokinetics (PK), pharmacodynamics (PD), and the different aspects of drug development and usage. Of particular interest to healthcare experts are absorption, distribution, metabolism, and excretion, the basic PK processes that must be understood to determine drug effects (Rosenthal & Burchum, 2021). The study of the processes involved in the interaction of drugs with the body, encompassed by PK and PD, is necessary for a better understanding of the work of medicines and their administration.
Absorption
The connection between PD and PK can be observed in absorption since the process’s specific aspects are associated with how drugs influence the body. Medications can be given via the intravascular (IV) and extravascular (EV) routes, each affecting how the substance moves. In the former case, medicines should cross cell membranes, and their ability to do so depends on each drug’s physicochemical properties.
In comparison, medications must be absorbed into the bloodstream and distributed to their target sites (Meesters et al., 2022). Since drugs enter via IV and EV routes, which move differently within the body, they also have distinct local and systemic effects (Migliorati et al., 2022). The rate of medication absorption also depends on solubility, with highly lipid-soluble drugs absorbed more quickly (Rosenthal & Burchum, 2021). This is due to their ability to cross the membranes, promptly separating them from the blood.
Distribution
The following necessary process that requires attention is drug distribution throughout the body. It represents the movement of a drug from the bloodstream into various human tissues and organs. Of particular importance in this context is paying attention to criteria such as volume of distribution.
It is a “proportionality constant that relates the total amount of drug in the body to the plasma concentration of the drug at a given time” (Mansoor & Mahabadi, 2023, para. 1). In other words, it shows the possibility of the drug remaining in human plasma or passing into tissues. This parameter is necessary to determine the drug dosage that should be prescribed to the patient.
Several factors impact the volume of drug distribution. These include lipophilicity, molecular weight, ionized state, and protein binding. The first aspect is the drug’s ability to dissolve in lipids or fat; that is, drugs can spread faster and more extensively in this type of tissue, which increases the volume of distribution.
Molecular weight affects the selected criterion due to the size of the molecules; that is, the smaller the molecule, the higher the indicator. The ionized state is influenced by drug characteristics, such as pKa, and the pH of the surrounding environment (Drug Hunter, 2022). Some drugs may be protein-bound, slowing the distribution process (Le, 2022). Thus, these factors significantly affect the distribution volume and must be considered.
Metabolism
The metabolism of a drug is a process that occurs for intravascular and extravascular routes of administration. It involves the biotransformation of polar, water-soluble drugs, facilitating their elimination. The liver is where these changes occur, but they can also occur in other organs and tissues. Several factors, particularly the volume of distribution, influence this process. The first of these is the primary site of metabolism, which, as already noted, is the liver. This is because they immediately enter this body during intravascular administration, and subsequent processing occurs from there.
The next influencing factor is oral versus intravenous drug metabolism. The first case is the “most commonly used state-of-the-art road for drug delivery” (Liu et al., 2022). It affects the metabolic rate because the first-pass effect is absent; the drug does not immediately enter the liver, as it does with intravenous drug metabolism.
Prodrug and non-prodrug metabolism also affect drug biotransformation. Hence, when characterizing prodrugs, they have inactive compounds, which, in the process of intravenous administration, significantly reduce their transition to an active form. A separate factor is phase I and phase II reactions, since in the first case, the drug, ug, undergoes oxidation, reduction, or hydrolysis, thereby accelerating biotransformation.
Excretion
Last but not least is the process of drug exclusion, which is the process of removing the drug from the body. There are several routes of excitement, including the kidney, liver, gut, lungs, and skin. They affect the rate of drug elimination from the body; for example, through kidney filtration into urine, which is the most common route. Moreover, aspects such as zero-order versus first-order PK also contribute.
In the first case, the removal process occurs at a constant rate regardless of the drug concentration, while in the second, this characteristic is decisive. Special attention should also be paid to half-life and steady-state criteria. Half-life is the “length of time required for the concentration of a drug to decrease to half of its starting dose in the body,” that is, the shorter it is, the faster excretion occurs (Hallare & Gerriets, 2023, para. 1). The last influence factor is steady state, which is characterized by the moment when the rate of drug administration corresponds to the elimination rate.
Conclusion
In conclusion, several essential processes must be considered when administering a particular medication. First of all, to what extent is the corporation absorbed, and what factors influence it? In addition, critical processes such as drug distribution through the body and its metabolism are also important. Ultimately, some criteria affect the rate at which the body clears the drug. This aspect is the most important component to consider when deciding on drug dosing and achieving therapeutic effectiveness.
References
Drug Hunter. (2022). Why pKas matter in medicinal chemistry and a drug discovery amine pKa table.
Hallare, J. & Gerriets, V. (2023). Half life. StatPearls.
Le, L. (2022). Drug distribution. MSD Manual.
Liu, L., Liu, Y., Zhou, X., Xu, Z., Zhang, Y., Ji, L., Hong, C., & Li, C. (2022). Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap. Frontiers in Pharmacology, 13.
Meesters, K., Alemayehu, T., Benou, S., Buonsenso, D., Decloedt, E. H., Pillay-Fuentes Lorente, V., Downes, K. J., & Allegaert, K. (2022). Pharmacokinetics of antimicrobials in children with emphasis on challenges faced by low and middle income countries, a clinical review. Antibiotics, 12(1), 1-23.
Migliorati, J. M., Liu, S., Liu, A., Gogate, A., Nair, S., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X. B. (2022). Absorption, distribution, metabolism, and excretion of US Food and Drug Administration–approved antisense oligonucleotide drugs. Drug Metabolism and Disposition, 50(6), 888-897.
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.